Eli Lilly and Company (LLY) Price Target Increased to $90.00 by Analysts at Morgan Stanley

Eli Lilly and Company (NYSE:LLY) had its target price raised by investment analysts at Morgan Stanley from $86.00 to $90.00 in a research report issued on Tuesday. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 8.20% from the company’s previous close.

Other research analysts also recently issued research reports about the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Barclays PLC increased their price objective on Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Cowen and Company reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $89.97.

Eli Lilly and (NYSE:LLY) traded up $0.29 on Tuesday, reaching $83.18. The company had a trading volume of 2,205,800 shares, compared to its average volume of 3,701,010. Eli Lilly and has a 1 year low of $64.18 and a 1 year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market cap of $91,950.00, a price-to-earnings ratio of 20.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 15.37% and a net margin of 9.82%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.88 EPS. research analysts anticipate that Eli Lilly and will post 4.21 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Company (LLY) Price Target Increased to $90.00 by Analysts at Morgan Stanley” was posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/21/eli-lilly-and-company-lly-price-target-increased-to-90-00-by-analysts-at-morgan-stanley.html.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 772,003 shares of company stock valued at $64,837,441. Company insiders own 0.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of LLY. Acrospire Investment Management LLC grew its position in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and during the second quarter valued at about $128,000. San Francisco Sentry Investment Group CA purchased a new stake in Eli Lilly and during the second quarter valued at about $129,000. Willingdon Wealth Management purchased a new stake in Eli Lilly and during the third quarter valued at about $138,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in Eli Lilly and during the third quarter valued at about $142,000. 76.61% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply